LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

随着靶向药物的迅猛发展，许多肺癌患者已经从EGFR、ALK、ROS1等靶向药中获益，实现了较长的生存期。然而，靶向药的“蜜月期”往往短暂——耐药问题迟早会找上门，患者和医生的共同敌人就是那无情的“耐药”。一旦靶向药失效，治疗手段就显得捉襟见肘，多数患 ...

Smith also points out that the focus on Dato-DXd has overshadowed AstraZeneca’s promising non-oncology pipeline, which is expected to deliver significant developments between 2025 and 2028.

Daiichi Sankyo Company (DSKYF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

AstraZeneca and Daiichi Sankyo have submitted a new biologics license application (BLA) for accelerated approval for ...

For more information visit ClinicalTrials.gov. Datopotamab deruxtecan (Dato-DXd) Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo's proprietary ...

During an exclusive interview with China News Network, Dato' Ong Chong Yi, Executive Director of BRI Caucus for Asia Pacific (BRICAP), said that ASEAN has embraced China's Belt and Road Initiative, ...